STOCKHOLM, Sweden, Dec. 20, 2013 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the company has decided to take direct responsibility for Orfadin® in the US, Canada, and Latin America by terminating the current distributorship agreement with their partner Rare Disease Therapeutics, Inc (RDT). Financial details were not disclosed.
"Our US subsidiary is ready to consistently and safely supply Orfadin to patients throughout the Americas, and we look forward to bringing a global perspective to partnering with Genetic and Metabolic physicians in serving the Tyrosinemia community in these territories," said Geoffrey McDonough, Sobi's CEO.
The distributorship will transfer to Sobi on 1 April 2014 for the US and Canada, and on 1 January 2015 for Latin America.
---
About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within hemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com
For more information - not for publication
| Media relations | Investor relations |
| Oskar Bosson, Head of Communications | Jörgen Winroth, Vice President, Head of Investor Relations |
| T: +46 70 410 71 80 | T: +46 8 697 20 00 |
| oskar.bosson@sobi.com | jorgen.winroth@sobi.com |
Press release (PDF) http://hugin.info/134557/R/1751522/590475.pdf
HUG#1751522